AI assistant
HAEMONETICS CORP — Director's Dealing 2024
May 21, 2024
31565_dirs_2024-05-21_1bac0e4a-f952-44af-837c-fc64f50f4c46.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-05-17
Reporting Person: Galvin Roy (President, Global Plasma & BC)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-17 | Common Stock | A | 2872 | — | Acquired | 7410 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | Non-qualified Stock Option (Right to Buy) | $95.73 | A | 6313 | Acquired | 2031-05-17 | Common Stock (6313) | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested RSUs previously reported.
F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.